Gilead Sciences
Gilead Sciences

GILD - Gilead Sciences • Dividends

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

See below the complete and updated table with all dividends paid and declared history, etc

Excluding DateValue (U$)Frequency
6/15/2026
0,82
Quarterly
3/13/2026
0,82
Quarterly
12/15/2025
0,79
Quarterly
9/15/2025
0,79
Quarterly
6/13/2025
0,79
Quarterly
3/14/2025
0,79
Quarterly
12/13/2024
0,77
Quarterly
9/13/2024
0,77
Quarterly
6/14/2024
0,77
Quarterly
3/14/2024
0,77
Quarterly
12/14/2023
0,75
Quarterly
9/14/2023
0,75
Quarterly
6/14/2023
0,75
Quarterly
3/14/2023
0,75
Quarterly
12/14/2022
0,73
Quarterly
9/14/2022
0,73
Quarterly
1/3

The latest dividend from GILD was $0.82 per share (ex-dividend 6/15/2026). The dividend yield over the last 12 months is 2,3%. Over the last 12 months there were 4 distributions, totalling $3.22 per share.